SCHEMBL19743601

SCHEMBL19743601

O=C(O)NCCOc1cccc(F)n1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.43
ADRA1A P35348 1/20 0.43
MTNR1A P48039 2/20 0.40
MTNR1B P49286 2/20 0.40
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 1/20 0.37
ATM Q13315 1/20 0.37
MAPK8 P45983 1/20 0.36
GPR52 Q9Y2T5 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16061881 0.85 HTR7 (0.51) MTNR1AMTNR1BHPGDSMN1; SMN2NPC1
SCHEMBL21383930 0.83 MTNR1A (0.44) HTR1AADRA1AMTNR1AMTNR1BHPGD
SCHEMBL28677773 0.81 SCN9A (0.49) HTR1AADRA1AKDM4EL3MBTL1
SCHEMBL19743711 0.78 HTR1A (0.44) HTR1AADRA1AMTNR1AMTNR1BHPGD
SCHEMBL19743715 0.78 NPC1 (0.39) MTNR1AMTNR1BHPGDSMN1; SMN2NPC1
SCHEMBL1953722 0.76 MTNR1A (0.46) HTR1AADRA1AMTNR1AMTNR1BHPGD
SCHEMBL19743714 0.76 ALDH1A1 (0.46) HTR1AADRA1AMTNR1AMTNR1BHPGD
SCHEMBL19743600 0.75 HTR1A (0.48) HTR1AADRA1ASMN1; SMN2ALDH1A1MAPT
SCHEMBL19743952 0.73 HTR1A (0.49) HTR1AADRA1ASMN1; SMN2NPC1RAB9A
SCHEMBL19743587 0.72 MAP2K7 (0.47) MTNR1AMTNR1BHPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3475268-B9 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2021-04-21 EP disclosed
EP-3475268-B1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2020-08-19 EP disclosed
US-10562853-B2 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors NEUROLIXIS (FR) 2020-02-18 US disclosed
US-20190194132-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2019-06-27 US disclosed
EP-3475268-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS Neurolixis (FR) 2019-05-01 EP disclosed
WO-2017220799-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2017-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562853-B2 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors HTR5A, HTR1A, HTR1E HTR1A 2/4885ADRA1A 18/4885MTNR1A 69/4885
US-20190194132-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS HTR5A, HTR1A, HTR1E HTR1A 2/4885ADRA1A 18/4885MTNR1A 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.